8-K: MAIA Biotechnology Secures $587,904 in Funding Through Stock Sale to Advance Phase 3 Lung Cancer Trial

MAIA Biotechnology, Inc. has entered into a stock purchase agreement with Prevail Partners, LLC to raise approximately $587,904, with proceeds earmarked to fund critical services for its ongoing Phase 3 clinical trial for advanced/metastatic non-small cell lung cancer.

Summary

• MAIA Biotechnology, Inc. (MAIA) entered into a Stock Purchase Agreement (SPA) with Prevail Partners, LLC on June 24, 2025.
• Under the SPA, MAIA will issue and sell approximately $587,904.34 worth of its common stock to Prevail Partners.
• The proceeds from this stock sale will be used to pay for technologies and services provided by Prevail InfoWorks, an affiliate of Prevail Partners.
• These services are for a multicenter, open-label, randomized Phase 3 study evaluating THIO sequenced with cemiplimab (LIBTAYO) as a third-line treatment for advanced/metastatic non-small cell lung cancer.
• The payment structure includes an upfront payment of $58,800.3333 in shares and thirty-six equal monthly tranche payments of $14,697.333 in shares.
• The per-share purchase price will be 120.0% of the 30-day volume-weighted average price (VWAP) on the NYSE, with a minimum share price set at $1.74.
• At the minimum price, a maximum of 337,876 shares can be issued.
• The agreement includes a 19.99% blocker, preventing the issuance of shares exceeding this percentage of outstanding common stock to comply with NYSE American rules without shareholder approval.

Sentiment

Score: 7

Explanation: The sentiment is positive as the company has successfully secured funding for a critical Phase 3 clinical trial, which is a significant de-risking event for a biotech company. While there is dilution, it's for a specific, high-value purpose.

Positives

• Secures funding for critical services related to the ongoing Phase 3 clinical trial for non-small cell lung cancer, which is a significant milestone for a biotechnology company.
• The funding mechanism is tied directly to the payment for services, ensuring the capital is used for its intended purpose of advancing the clinical trial.
• The agreement with Prevail Partners, an accredited investor, indicates a strategic partnership that supports the company's R&D efforts.

Negatives

• The issuance of new shares will result in dilution for existing shareholders.
• The share price for the sale is set at 120.0% of the 30-day VWAP, which could be seen as a premium, but the minimum price of $1.74 acts as a floor, potentially below current market price if the stock drops.
• The funding is specifically for services from an affiliate of the investor, which, while strategic, limits the company's flexibility in allocating these specific funds.

Risks

• Dilution Risk: The issuance of new common stock will dilute the ownership percentage of existing shareholders.
• Regulatory Compliance Risk: The Company must comply with NYSE American rules regarding share issuance, including the 19.99% Exchange Cap, which may require stockholder approval for issuances exceeding this limit.
• Clinical Trial Risk: The success of the Phase 3 study is crucial, and failure to achieve positive results could negatively impact the company's prospects and stock value.
• Market Price Volatility: The share price for future tranches is tied to VWAP, meaning the number of shares issued will fluctuate with the stock price, potentially leading to more dilution if the stock price declines.

Future Outlook

The agreement secures funding for the continuation of the multicenter, open-label, randomized Phase 3 study evaluating THIO sequenced with cemiplimab (LIBTAYO) as a third-line treatment for advanced/metastatic non-small cell lung cancer. This indicates a clear path forward for the clinical development of this therapeutic candidate.

Management Comments

• "MAIA Biotechnology, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized." (Vlad Vitoc, CEO)

Industry Context

This transaction is typical for a clinical-stage biotechnology company like MAIA, which relies on external funding to advance its drug candidates through costly clinical trials. Securing funding for a Phase 3 trial, especially for a significant indication like non-small cell lung cancer, is a critical step in the drug development lifecycle. The use of a stock purchase agreement tied to service payments is a specific financing mechanism that aligns the investor's interest with the operational progress of the clinical trial.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to benchmark against.
• However, securing funding for a Phase 3 clinical trial is a standard and necessary step for biotech companies, as these trials are capital-intensive.
• The financing structure, tying stock issuance to payments for specific clinical trial services, is a less common but strategic approach that ensures funds are directly applied to operational needs rather than general working capital.
• The 19.99% NYSE American blocker is a standard regulatory compliance measure for equity issuances without shareholder approval.

Related Party Transactions

• MAIA Biotechnology, Inc. entered into a Stock Purchase Agreement with Prevail Partners, LLC, where the proceeds are specifically designated to pay for services provided by Prevail InfoWorks, Inc., an affiliate of Prevail Partners, LLC. This constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Will experience dilution due to the issuance of new common stock. However, the funding supports the advancement of a key clinical asset, which could potentially increase long-term shareholder value if the trial is successful.
• Employees: The funding helps ensure the continuation of the Phase 3 clinical trial, supporting the company's core operations and potentially job security related to the trial's progress.
• Customers (future patients): The funding directly supports the development of a potential new treatment for advanced/metastatic non-small cell lung cancer, offering hope for future therapeutic options.
• Creditors: No direct impact mentioned, but securing funding for operations generally improves financial stability.

Next Steps

• Continuation of the multicenter, open-label, randomized Phase 3 study evaluating THIO sequenced with cemiplimab (LIBTAYO) vs. Investigator choice of single-agent chemotherapy as third-line treatment in subjects with advanced/metastatic non-small cell lung cancer.
• Monthly issuance of shares to Prevail Partners based on 33% of paid invoices for InfoWorks' direct expenses.
• Potential requirement for stockholder approval if share issuances exceed the 19.99% Exchange Cap.

Key Dates

Recommendation

Keywords

MAIA Biotechnology, SEC Filing, 8-K, Stock Purchase Agreement, Capital Raise, Equity Financing, Phase 3 Clinical Trial, Non-Small Cell Lung Cancer, THIO, Cemiplimab, LIBTAYO, Biotechnology, Pharmaceuticals, Clinical Development, Prevail Partners, Prevail InfoWorks, Dilution, NYSE American